BRAF mutation in papillary thyroid carcinoma

Journal of the National Cancer Institute

Volumn 95, Issue 8, 2003, Pages 625-627

  Cohen, Yoram ^a   Xing, Mingzhao ^a   Mambo, Elizabeth ^a   Gou, Zhongmin ^a   Wu, Guogun ^a   Trink, Barry ^a   Beller, Uziel ^b   Westra, William H ^a   Ladenson, Paul W ^a   Sidransky, David ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE; B RAF KINASE; RAF PROTEIN; THYMINE; UNCLASSIFIED DRUG;

ARTICLE; BLADDER CANCER; CARCINOGENESIS; CONTROLLED STUDY; EXON; GENE ACTIVATION; GENE MUTATION; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; LUNG CANCER; MAJOR CLINICAL STUDY; MELANOMA; MISSENSE MUTATION; NUCLEIC ACID BASE SUBSTITUTION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE CANCER; RESTRICTION MAPPING; THYROID CANCER; THYROID PAPILLARY CARCINOMA; UTERINE CERVIX CANCER;

EID: 0038664387     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/95.8.625     Document Type: Article

References (12)

1. Peyssonnaux C, Eychene A. The Raf/MEK/ERK pathway: new concepts of activation. Biol Cell 2001;93:53-62.
2. Duesbery NS, Webb CP, Vande Woude GF. MEK wars, a new front in the battle against cancer. Nat Med 1999;5:736-7.
3. Avruch J, Khokhlatchev A, Kyriakis JM, Luo Z, Tzivion G, Vavvas D, et al. Ras activation of the Raf kinase: tyrosine kinase recruitment of the MAP kinase cascade. Recent Prog Horm Res 2001;56:127-55.
4. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417:949-54.
5. Gimm O. Thyroid cancer. Cancer Lett 2001; 163:143-56.
6. Grieco M, Santoro M, Berlingieri MT, Melillo RM, Donghi R, Bongarzone I, et al. PTC is a novel rearranged form of the ret protooncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell 1990;60:557-63.
7. Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 2002;418: 934.
8. Singer G, Oldt R III, Cohen Y, Wang BG, Sidransky D, Kurman RJ, et al. Mutations in BRAF and KRAS characterize the development of low-grade serous ovarian carcinoma. J Natl Cancer Inst. In press 2003.
9. Ludwig L, Kessler H, Wagner M, Hoang-Vu C, Dralle H, Adler G, et al. Nuclear factor-kappaB is constitutively active in C-cell carcinoma and required for RET-induced transformation. Cancer Res 2001;61:4526-35.
10. Saavedra HI, Knauf JA, Shirokawa JM, Wang J, Ouyang B, Elisei R, et al. The RAS oncogene induces genomic instability in thyroid PCCL3 cells via the MAPK pathway. Oncogene 2000;19:3948-54.
11. Specht MC, Barden CB, Fahey TJ 3rd. p44/p42-MAP kinase expression in papillary thyroid carcinomas. Surgery 2001;130:936-40.
12. Lyons JF, Wilhelm S, Hibner B, Bollag G. Discovery of a novel Raf kinase inhibitor. Endocr Relat Cancer 2001;8:219-25.